DeSchepper PJ - Search Results

1

Biochemical activity, pharmacokinetics, and tolerability of MK-886, a leukotriene biosynthesis inhibitor, in humans.

Depre M, Friedman B, Tanaka W, Van Hecken A, Buntinx A, DeSchepper PJ. Depre M, et al. Among authors: deschepper pj. Clin Pharmacol Ther. 1993 May;53(5):602-7. doi: 10.1038/clpt.1993.76. Clin Pharmacol Ther. 1993. PMID: 8387904 Clinical Trial.

2

Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model.

Ehrich EW, Dallob A, De Lepeleire I, Van Hecken A, Riendeau D, Yuan W, Porras A, Wittreich J, Seibold JR, De Schepper P, Mehlisch DR, Gertz BJ. Ehrich EW, et al. Clin Pharmacol Ther. 1999 Mar;65(3):336-47. doi: 10.1016/S0009-9236(99)70113-X. Clin Pharmacol Ther. 1999. PMID: 10096266 Clinical Trial.

3

Tolerance and pharmacokinetics of propacetamol, a paracetamol formulation for intravenous use.

Depré M, van Hecken A, Verbesselt R, Tjandra-Maga TB, Gerin M, de Schepper PJ. Depré M, et al. Fundam Clin Pharmacol. 1992;6(6):259-62. doi: 10.1111/j.1472-8206.1992.tb00119.x. Fundam Clin Pharmacol. 1992. PMID: 1487229 Clinical Trial.

4

Human pharmacokinetics and tolerability of L-697,639, a non-nucleoside HIV-1 reverse transcriptase inhibitor.

Van Hecken A, Depre M, De Lepeleire I, Laskin O, Au T, Woolf E, Yeh KC, De Schepper PJ. Van Hecken A, et al. Int J Clin Pharmacol Res. 1994;14(2):45-50. Int J Clin Pharmacol Res. 1994. PMID: 7530697 Clinical Trial.

5

Pharmacokinetics and pharmacodynamics of multiple oral doses of MK-0591, a 5-lipoxygenase-activating protein inhibitor.

Depré M, Friedman B, Van Hecken A, de Lepeleire I, Tanaka W, Dallob A, Shingo S, Porras A, Lin C, de Schepper PJ. Depré M, et al. Clin Pharmacol Ther. 1994 Jul;56(1):22-30. doi: 10.1038/clpt.1994.96. Clin Pharmacol Ther. 1994. PMID: 8033491 Clinical Trial.

6

Plasma concentrations and effect on testosterone metabolism after single doses of MK-0434, a steroid 5 alpha-reductase inhibitor, in healthy subjects.

Van Hecken A, Depré M, Schwartz JI, Tjandramaga TB, Winchell GA, De Lepeleire I, Ng J, De Schepper PJ. Van Hecken A, et al. Eur J Clin Pharmacol. 1994;46(2):123-6. doi: 10.1007/BF00199874. Eur J Clin Pharmacol. 1994. PMID: 8039530

7

Moexipril does not alter the pharmacokinetics or pharmacodynamics of warfarin.

Van Hecken A, Verbesselt R, Depré M, Tjandramaga TB, Angehrn J, Cawello W, De Schepper PJ. Van Hecken A, et al. Eur J Clin Pharmacol. 1993;45(3):291-3. doi: 10.1007/BF00315400. Eur J Clin Pharmacol. 1993. PMID: 8276058 Clinical Trial.

8

Biochemical activity, pharmacokinetics and tolerability of tepoxalin, a cyclooxygenase/5-lipoxygenase inhibitor, in man.

Depré M, Van Hecken A, Verbesselt R, Verpooten GA, Arnout J, Brunner F, Jurgens A, Pousset V, Chow A, Baldauf C, Vermylen J, De Broe M, De Schepper PJ. Depré M, et al. Int J Clin Pharmacol Res. 1996;16(1):1-8. Int J Clin Pharmacol Res. 1996. PMID: 9001924 Clinical Trial.

9

Pharmacokinetic and pharmacodynamic interaction between the lipoxygenase inhibitor MK-0591 and the cyclooxygenase inhibitor ibuprofen in man.

Depré M, Van Hecken A, Verbesselt R, De Lepeleire I, Schwartz J, Porras A, Larson P, Lin C, De Schepper PJ. Depré M, et al. Int J Clin Pharmacol Res. 1998;18(2):53-61. Int J Clin Pharmacol Res. 1998. PMID: 9675622 Clinical Trial.

10

Effect of montelukast on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers.

Van Hecken A, Depré M, Verbesselt R, Wynants K, De Lepeleire I, Arnout J, Wong PH, Freeman A, Holland S, Gertz B, De Schepper PJ. Van Hecken A, et al. J Clin Pharmacol. 1999 May;39(5):495-500. J Clin Pharmacol. 1999. PMID: 10234597 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

94 results

Search Page

Filters